If you want to take Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight management, you might also be exploring telemedicine and the convenience of getting a ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...

As with any prescription medication, there are side effects of Wegovy to keep in mind. The most common side effects are gastrointestinal ones, like: Some foods may aggravate these side effects ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

For Debbie Halstead, the weight loss medication Wegovy has been nothing short of a miracle. The Cool Ridge, West Virginia, woman shed 60 pounds and lowered her blood pressure nearly 60 points.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head randomized controlled trial. The result ...